Literature DB >> 18583112

Reovirus: viral therapy for cancer 'as nature intended'.

C Comins1, L Heinemann, K Harrington, A Melcher, J De Bono, H Pandha.   

Abstract

Oncolytic viruses are tumour selective and able to lyse cancer cells after infection. Reovirus is an example of a wild-type oncolytic virus and is currently being investigated as a potential novel therapy for cancer. This overview gives a brief description of what is known about reovirus biology and summarises the preclinical data related to its oncolytic ability. The completed and ongoing clinical trials involving reovirus, both as a single agent and in combination with chemotherapy and radiotherapy, will be reviewed and their results discussed. Many of these clinical studies are being conducted by centres in the UK.

Entities:  

Mesh:

Year:  2008        PMID: 18583112     DOI: 10.1016/j.clon.2008.04.018

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  21 in total

1.  REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

Authors:  Charles Comins; James Spicer; Andrew Protheroe; Victoria Roulstone; Katie Twigger; Christine M White; Richard Vile; Alan Melcher; Matt C Coffey; Karl L Mettinger; Gerard Nuovo; David E Cohn; Mitch Phelps; Kevin J Harrington; Hardev S Pandha
Journal:  Clin Cancer Res       Date:  2010-10-06       Impact factor: 12.531

2.  Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

Authors:  Timothy Kottke; Geoff Hall; Jose Pulido; Rosa Maria Diaz; Jill Thompson; Heung Chong; Peter Selby; Matt Coffey; Hardev Pandha; John Chester; Alan Melcher; Kevin Harrington; Richard Vile
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

Review 3.  Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Authors:  Jun Gong; Esha Sachdev; Alain C Mita; Monica M Mita
Journal:  World J Methodol       Date:  2016-03-26

4.  Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.

Authors:  Elizabeth J Ilett; Montserrat Bárcena; Fiona Errington-Mais; Stephen Griffin; Kevin J Harrington; Hardev S Pandha; Matthew Coffey; Peter J Selby; Ronald W A L Limpens; Mieke Mommaas; Rob C Hoeben; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2011-03-09       Impact factor: 12.531

5.  Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples.

Authors:  Gerard J Nuovo; Michela Garofalo; Nicola Valeri; Vicki Roulstone; Stefano Volinia; David E Cohn; Mitch Phelps; Kevin J Harrington; Richard Vile; Alan Melcher; Evanthia Galanis; Sarah Sehl; Rob Adair; Karen Scott; Ailsa Rose; Giles Toogood; Matthew C Coffey
Journal:  Mod Pathol       Date:  2012-06-15       Impact factor: 7.842

6.  Current status of gene therapy for brain tumors.

Authors:  Andrea M Murphy; Samuel D Rabkin
Journal:  Transl Res       Date:  2012-12-11       Impact factor: 7.012

7.  Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Authors:  E J Ilett; R J Prestwich; T Kottke; F Errington; J M Thompson; K J Harrington; H S Pandha; M Coffey; P J Selby; R G Vile; A A Melcher
Journal:  Gene Ther       Date:  2009-03-12       Impact factor: 5.250

Review 8.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Authors:  David H Kirn; Steve H Thorne
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

9.  Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Authors:  Robin J Prestwich; Elizabeth J Ilett; Fiona Errington; Rosa M Diaz; Lynette P Steele; Tim Kottke; Jill Thompson; Feorillo Galivo; Kevin J Harrington; Hardev S Pandha; Peter J Selby; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

10.  Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?

Authors:  Mahua Dey; Brenda Auffinger; Maciej S Lesniak; Atique U Ahmed
Journal:  Future Virol       Date:  2013-07       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.